This week's biggest % winners & losers : Dec 9 - 13, 19 (wk 50)

The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top % gainers

• Healthcare: THOR (68.03 +171.79%), ARQL (20.07 +107.6%), DERM (12.7 +61.17%), TGTX (10.1 +41.85%), FATE (18.79 +37.45%), CLVS (12.86 +33.82%), ASMB (21.46 +30.61%), AMRX (4.76 +29.35%), ITCI (12.83 +25.74%), RUBY (13.11 +23.45%), DCPH (64.63 +22.41%)
• Industrials: BE (6.78 +28.41%)
• Information Technology: PLAB (15.94 +29.07%), ARLO (4.21 +28.35%)
• Energy: AM (5.85 +30.29%), AR (2.69 +22.83%), DNR (1.26 +22.33%)

This week's top % losers

• Healthcare: SGMO (8.51 -27.02%), OMI (5.51 -26.92%), ATNX (14.55 -18.03%), NXGN (14.77 -17.51%), MDGL (97.45 -16.85%), SPPI (8.36 -15.04%)
• Consumer Discretionary: CONN (12.59 -35.17%), LOVE (10.74 -28.21%), PLCE (54.11 -22.51%), VNCE (17.37  -21.76%), GME (5.45 -18.41%), DBI (15.04  -9.56%)
• Information Technology: PI (26.03 -15.43%)
• Financials: SBT (7.13 -24.55%), TREE (288.86 -17.67%)
• Consumer Staples: UNFI (6.84 -29.48%)

=ArQule (ARQL) to be acquired by Merck (MRK) for $20 per share

  

ArQule to be acquired by Merck (MRK) for $20 per share in cash for an approximate total equity value of $2.7 billion

Cos have entered into a definitive agreement under which Merck, through a subsidiary, will acquire ArQule for $20 per share in cash for an approximate total equity value of $2.7 billion. ArQule is a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. ArQule's lead investigational candidate, ARQ 531, is a novel, oral Bruton's tyrosine kinase (BTK) inhibitor currently in a Phase 2 dose expansion study for the treatment of B-cell malignancies.

Under the terms of the acquisition agreement announced today, Merck, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of ArQule. The closing of the tender offer will be subject to certain conditions, including the tender of shares representing at least a majority of the total number of ArQule's outstanding shares, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. Upon the successful completion of the tender offer,

Merck's acquisition subsidiary will be merged into ArQule, and any remaining shares of common stock of ArQule will be canceled and converted into the right to receive the same $20 per share price payable in the tender offer. The transaction is expected to close early in the first quarter of 2020.

Long trade : ARQL +100% (5/18)

• A month later